Biogen Opts To Retain Biosimilars Business
After Strategic Review, Firm Decides To ‘Optimize’ Its Interests In Biosimilars
Following a “comprehensive review” of its biosimilars business – including exploring options to sell the unit – Biogen has decided to retain it after all, and is instead planning to “optimize the business with an aim to maximize profitability.”
